{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,25]],"date-time":"2025-06-25T04:10:50Z","timestamp":1750824650851,"version":"3.41.0"},"reference-count":12,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,12,1]],"date-time":"2017-12-01T00:00:00Z","timestamp":1512086400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","lungcancerjournal.info","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1016\/j.lungcan.2017.07.027","type":"journal-article","created":{"date-parts":[[2017,7,25]],"date-time":"2017-07-25T02:16:35Z","timestamp":1500948995000},"page":"103-105","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Need for randomized clinical trials testing targeted therapies in malignant pleural mesothelioma"],"prefix":"10.1016","volume":"114","author":[{"given":"N.","family":"Sobhani","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Roviello","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.P.","family":"Corona","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Ianza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Zanconati","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Generali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.lungcan.2017.07.027_bib0005","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1007\/s12199-007-0017-6","article-title":"Pathology of mesothelioma","volume":"13","author":"Inai","year":"2008","journal-title":"Environ. Health Prev. Med."},{"key":"10.1016\/j.lungcan.2017.07.027_bib0010","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/S0002-9343(03)00087-1","article-title":"Simian virus 40 in human cancers","volume":"114","author":"Vilchez","year":"2003","journal-title":"Am. J. Med."},{"key":"10.1016\/j.lungcan.2017.07.027_bib0015","first-page":"1524","article-title":"SV40 induces mesotheliomas in hamsters","volume":"142","author":"Cicala","year":"1993","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.lungcan.2017.07.027_bib0020","doi-asserted-by":"crossref","first-page":"10214","DOI":"10.1073\/pnas.170207097","article-title":"Human mesothelial cells are unusually susceptible to simian virus 40-mediated transformation and asbestos cocarcinogenicity","volume":"97","author":"Bocchetta","year":"2000","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.lungcan.2017.07.027_bib0025","doi-asserted-by":"crossref","DOI":"10.1183\/20734735.001011","article-title":"Mesothelioma: an update","volume":"8","author":"Berghmans","year":"2011","journal-title":"Breathe"},{"key":"10.1016\/j.lungcan.2017.07.027_bib0030","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1200\/JCO.2003.11.136","article-title":"Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma","volume":"21","author":"Vogelzang","year":"2003","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2017.07.027_bib0035","doi-asserted-by":"crossref","first-page":"6881","DOI":"10.1200\/JCO.20005.14.589","article-title":"Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute","volume":"23","author":"J","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2017.07.027_bib0040","first-page":"719","article-title":"Statistical aspects of the analysis of data from retrospective studies of disease","volume":"22","author":"Mantel","year":"1959","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.lungcan.2017.07.027_bib0045","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Control. Clin. Trials"},{"key":"10.1016\/j.lungcan.2017.07.027_bib0050","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1016\/S0140-6736(15)01238-6","article-title":"French cooperative thoracic intergroup (IFCT), bevacizumab for newly diagnosed pleural mesothelioma in the mesothelioma avastin cisplatin pemetrexed study (MAPS): a randomised controlled, open-label, phase 3 trial","volume":"387","author":"Zalcman","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.lungcan.2017.07.027_bib0055","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/S1470-2045(13)70125-6","article-title":"Thalidomide versus active supportive care for maintenance in patients with malignant mesothelioma after first-line chemotherapy (NVALT 5): an open-label, multicentre, randomised phase 3 study","volume":"14","author":"WA","year":"2013","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.lungcan.2017.07.027_bib0060","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/S1470-2045(15)70056-2","article-title":"Vorinostat in patients with advanced malignant pleural mesothelioma who have progressed on previous chemotherapy (VANTAGE-014): a phase 3, double-blind, randomised, placebo-controlled trial","volume":"16","author":"LM","year":"2015","journal-title":"Lancet Oncol."}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500217304154?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500217304154?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,24]],"date-time":"2025-06-24T17:41:49Z","timestamp":1750786909000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500217304154"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12]]},"references-count":12,"alternative-id":["S0169500217304154"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2017.07.027","relation":{},"ISSN":["0169-5002"],"issn-type":[{"type":"print","value":"0169-5002"}],"subject":[],"published":{"date-parts":[[2017,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Need for randomized clinical trials testing targeted therapies in malignant pleural mesothelioma","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2017.07.027","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}